Kusatsu/Shiga, Japan — September 24, 2019 – Takara Bio Inc. (Takara Bio) announces that the results from clinical trials of C-REV (canerpaturev, former HF10), an oncolytic viral immunotherapy and NY-ESO-1・siTCR™ gene therapy will be presented at the 2019 Annual Meeting of the European Society for Medical Oncology (September 27 – October 1, 2019, Barcelona, Spain).
|
Title and Presentation Date |
|---|
|
September 29 Results from phase I study of the oncolytic immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer
|
|
September 29 Phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) with S-1 in patients with stage IV pancreatic cancer
|
|
September 30 Final Results from Phase II of Combination with Canerpaturev (formerly HF10), an Oncolytic Viral Immunotherapy, and Ipilimumab in Unresectable or Metastatic Melanoma in 2nd-or later line treatment
|
|
September 28 A novel affinity-enhanced NY-ESO-1 targeting TCR-redirected T cell transfer exhibited early-onset cytokine release syndrome and subsequent tumor responses in synovial sarcoma patients
|
|
September 28 Adoptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumor responses in patients with NY-ESO-1 expressing solid tumors
|
